Oncorus, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ONCR research report →
Price Chart
About the company
Oncorus, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering viral immunotherapies designed to combat cancer in patients. At the forefront of its pipeline is ONCR-177, an innovative viral immunotherapy that leverages a modified herpes simplex virus type 1 (oHSV-1) platform.
- CEO
- Craig R. Jalbert CIRA
- IPO
- 2020
- Employees
- 64
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on ONCR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $0
- P/E
- -0.04
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.05
- EV/EBITDA
- -0.59
- Div Yield
- 110.58%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -82.19%
- ROIC
- -59.36%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-76,537,000
- Net Income
- $-78,307,000-21.0%
- EPS
- $-3.02-18.0%
- OCF Growth
- -23.8%
- FCF Growth
- -37.5%
- 52W High
- $0.47
- 52W Low
- $0.01
- 50D MA
- $0.03
- 200D MA
- $0.10
- Beta
- 1.95
- RSI (14)
- 90
- Avg Volume
- 108.67K
No earnings-call transcripts are available for ONCR yet.
of shares held by institutions
4 13F filers
Buy/sell ratio 0.04. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Marshall Wace North America L.P. | 309.89K | 0 |
| Parametric Portfolio Associates LLC | 55.35K | ▲ 41.62K |
| Next Financial Group, Inc | 7.56K | ▲ 7.56K |
| Amalgamated Financial Corp. | 2.46K | ▲ 2.46K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 6, 23 | Shea Brian J. | other | 0 |
| Jun 6, 23 | Shea Brian J. | other | 0 |
| Jun 6, 23 | Shea Brian J. | other | 0 |
| Jun 6, 23 | Shea Brian J. | other | 0 |
| Jun 6, 23 | Shea Brian J. | other | 0 |
| May 9, 23 | Nolte Alexander | other | 0 |
| Dec 28, 22 | Flynn James E | sell | 24,757 |
| Dec 29, 22 | Flynn James E | sell | 63,107 |
| Dec 29, 22 | Flynn James E | sell | 63,108 |
| Dec 30, 22 | Flynn James E | sell | 61,826 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ONCR coverage
Recent articles, reports, and earnings notes.
No research on ONCR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ONCR report →Why Is Oncorus (ONCR) Stock Down 27% Today?
investorplace.com · Jun 12
Oncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy Threat
zacks.com · Jun 5
Oncorus to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 23
Oncorus, Inc. (ONCR) Moves to Buy: Rationale Behind the Upgrade
zacks.com · Nov 7
Oncorus to Present at Chardan's 6th Annual Genetic Medicines Conference
globenewswire.com · Sep 26
Oncorus to Present at the H.C. Wainwright 24th Annual Global Investment Conference
globenewswire.com · Sep 6
Here's Why Oncorus, Inc. (ONCR) Looks Ripe for Bottom Fishing
zacks.com · Jul 13
Oncorus to Present at the Jefferies Global Healthcare Conference
globenewswire.com · Jun 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.